Although it had long been suspected that obesity ages a person faster, it hadn’t been possible to prove the theory, said study first author Steve Horvath, a professor of human genetics at the David Geffen School of Medicine at UCLA and a professor of biostatistics at the UCLA Fielding School of Public Health. …
“This drug delivery system is DNA-based, which means it is biocompatible and less toxic to patients than systems that use synthetic materials,” says Dr. Zhen Gu, senior author of a paper on the work and an assistant professor in the joint biomedical engineering program at NC State and UNC Chapel Hill. …
“While laboratory studies support an important role for cholesterol in prostate cancer, population-based evidence linking cholesterol and prostate cancer is mixed,” said Emma Allott, PhD, postdoctoral associate at Duke University School of Medicine in Durham, North Carolina. “Understanding associations between obesity, cholesterol, and prostate cancer is important given that cholesterol levels are readily modifiable with diet and/or statin use, and could therefore have important, practical implications for prostate cancer prevention and treatment. “Our findings suggest that normalization, or even partial normalization, of serum lipid levels among men with dyslipidemia [abnormal lipid profile] may reduce the risk of prostate cancer recurrence,” said Allott. …
“While laboratory studies support an important role for cholesterol in prostate cancer, population-based evidence linking cholesterol and prostate cancer is mixed,” said Emma Allott, PhD, postdoctoral associate at Duke University School of Medicine in Durham, North Carolina. “Understanding associations between obesity, cholesterol, and prostate cancer is important given that cholesterol levels are readily modifiable with diet and/or statin use, and could therefore have important, practical implications for prostate cancer prevention and treatment. “Our findings suggest that normalization, or even partial normalization, of serum lipid levels among men with dyslipidemia [abnormal lipid profile] may reduce the risk of prostate cancer recurrence,” said Allott. Allott, Stephen Freedland, MD, associate professor of surgery at Duke University School of Medicine, and colleagues, analyzed data from 843 men who underwent radical prostatectomy after a prostate cancer diagnosis and who never took statins before surgery. …
“Colorectal cancer is still one of the most frequent and deadliest cancers worldwide. But diagnosed in time it can be cured in 9 out of 10 cases,” said Professor Serge Haan from the Life Science Research Unit at the University of Luxembourg…
The report entitled ‘Osteoporosis in men: why change needs to happen’ is released ahead of World Osteoporosis Day on October 20, and highlights that the ability of men to live independent pain-free lives into old age is being seriously compromised. …
Johns Hopkins Kimmel Cancer Center scientists first used cyclophosphamide to prevent severe graft-versus-host disease (GVHD) after bone marrow transplant involving haploidentical or “half-matched” transplants, a treatment first used in 2000 at the Cancer Center to treat leukemias and other blood cancers. The scientists began to use post-transplant cyclophosphamide in clinical trials of fully matched bone marrow transplants in 2004. Now, the new multi-center study confirms that the post-transplant cyclophosphamide is safe and effective for people who have received fully-matched bone marrow transplants. The shortened regimen, described online Sept. …
Although salivary gland cancer is rare, this retrospective study suggests it occurs 17 times more often in people with inherited mutations in genes called BRCA1 and BRCA2, than those in the general population. “Further study is needed to confirm this preliminary result, but I believe that a BRCA-positive patient with a lump in a salivary gland should have that lesion evaluated as soon as possible,” says co-author Theodoros Teknos, MD, professor and chair of otolaryngology, director of head and neck oncologic surgery, and the David E…
It’s known that stem cells come out of the bone marrow and travel to the tiny thymus gland behind the breastbone to learn to become one of two CD4T cell types: one leads an attack, the other keeps the peace. One widely held concept of why they become one or the other is that, despite coming from the same neighborhood and going to the same school, they are exposed to different things in the thymus, said Dr. Leszek Ignatowicz, immunologist at the Medical College of Georgia at Georgia Regents University. In this case, the “things” are ligands and developing T cells are potentially exposed to thousands of these tiny pieces of us inside the thymus…
“Previous journal articles never clearly differentiated GIST from several other tumors, even though they have different biologies,” said Jason Sicklick, MD, assistant professor of surgery and a surgical oncologist at UC San Diego Health System. “This study more clearly identifies at-risk populations in the United States as well as incidence rates, survival trends and risk factors for the disease.” Prior to 2001, GIST-specific histology codes were not used in medical coding, which meant that a variety of tumor types, such as leiomyoma and leiomyosarcoma, spindle cell, myofibroblastic, desmoid and KIT-positive metastatic melanomas were all lumped into one category. Sicklick and his team have used a new generation of precise pathologic diagnostic codes to better define the incidence and distribution of GIST among different patient groups. The research team from UC San Diego Moores Cancer Center found that the overall incidence rate was 6.8 cases per million people and that the rate rose from 2001 to 2011. …